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Patterns of Cerebral Glucose Metabolism 
Detected with Positron Emission 
Tomography Dfier in Multiple System 
Atrophy and Olivopontocerebellar Atrophy 
Sid Gilman, MD,” Robert A. Koeppe, PhD,? Larry Junck, MD,” Karen J. Kluin, MS,*$ 
Mary Lohman, BA,“ and Roy T. St Laurent, PhDg 
We used positron emission tomography with {‘8F7fluorodeoxyglucose to study local cerebral metabolic rates for glucose 
(ICMRglc) in patients with multiple system atrophy (MSA), sporadic olivopontocerebellar atrophy (sOPCA), and 
dominantly inherited olivopontocerebellar atrophy (dOPCA) in comparison with normal control subjects. In MSA, 
absolute ICMRglc was significantly decreased in the brainstem, cerebellum, putamen, thalamus, and cerebral cortex. 
In sOPCA, absolute 1CMRglc was significantly decreased in the brainstem, cerebellum, putamen, thalamus, and cere- 
bral cortex. In dOPCA, absolute ICMRglc was significantly decreased in the brainstem and cerebellum but not in the 
other structures. Examination of ICMRglc normalized to the cerebral cortex in comparison with normal controls 
revealed in MSA significant decreases in the brainstem, cerebellum, and putamen but, in both sOPCA and dOPCA, 
significant decreases only in the brainstem and cerebellum. The findings indicate that these three disorders all show 
a marked decrease of ICMRglc in the brainstem and cerebellum but differ in the degree of hypometabolism in 
forebrain and cerebral cortical structures. The results are consistent with the possibility that, in many cases, sOPCA 
will evolve into MSA. Moreover, positron emission tomography may provide helpful diagnostic information in these 
neurodegenerative diseases. 
Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St Laurent RT. Patterns of cerebral glucose 
metabolism detected with positron emission tomography differ in multiple system 
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Multiple system atrophy (MSA) is an adult-onset spo- 
radic neurodegenerative disease presenting clinically 
with symptoms and signs of extrapyramidal, cerebellar, 
and autonomic dysfunction in various combinations 
[1-5}. The extrapyramidal symptoms are poorly re- 
sponsive or unresponsive to levodopa therapy C6, 7). 
The neuropathological features of MSA consist of de- 
generative changes, including neuronal loss and gliosis, 
in the basal ganglia (putamen and globus pallidus), 
brainstem and cerebellum (substantia nigra, locus ceru- 
leus, dorsal vagal nuclei, vestibular nuclei, inferior ol- 
ives, pontine nuclei, and cerebellar Purkinje cells), and 
spinal cord (pyramidal tracts, intermediolateral col- 
umns, and Onuf’s nuclei) C2, 4, 81. Other central ner- 
vous system structures that can be affected include the 
optic nerves, cerebral cortex, caudate nuclei, subtha- 
l a i c  nuclei, red nuclei, dentate nuclei, anterior horn 
cells, and sympathetic ganglia C2, 41. 
Several neurological diseases are considered to be 
subgroups of MSA, including striatonigral degenera- 
tion (SND) 19-12], Shy-Drager syndrome (SDS) C1, 
3, 13-15], and olivopontocerebellar atrophy (OPCA) 
with autonomic insufficiency or extrapyramidal disor- 
ders [2, 16-23]. When detected without autonomic 
insufficiency or cerebellar disorder, SND is considered 
to be “possible MSA,” whereas SDS and OPCA with 
autonomic insufficiency or extrapyramidal disorders 
are considered to be “probable MSA” C4f. In SND 
the neuropathological changes affect chiefly the basal 
ganglia and substantia nigra, in SDS the brainstem and 
spinal cord, and in OPCA the inferior olives, pons, and 
cerebellum. 
There is substantial overlap in symptoms, signs, and 
neuropathological changes in SND, SDS, and OPCA 
and thus strong justification for considering them all 
potentially as forms of MSA [4]. Some patients with 
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MSA initially develop extrapyramidal symptoms and 
later experience autonomic or cerebellar symptoms or 
both [41. Others first manifest cerebellar symptoms 
and later develop autonomic or extrapyramidal symp- 
toms. Although signs of cerebellar dysfunction may 
not be evident in patients who develop SND or SDS, 
neuropathological studies demonstrate degenerative 
changes in the cerebellum and brainstem in most cases 
[S}. The loss of cerebellar and brainstem neurons is 
greatest in patients with MSA presenting initially with 
cerebellar symptoms, less in those with SDS, and least 
in those with SND {S]. In some patients, especially 
those with hereditary disease, OPCA occurs without 
involving the extrapyramidal or autonomic systems. In 
others, mostly in sporadic cases, OPCA can progress 
to MSA. Currently no method is available to determine 
whether sporadic OPCA will progress to include other 
manifestations of MSA. 
Previously, using [l8F1fluorodeoxyglucose (FDG) 
and positron emission tomography (PET), we demon- 
strated hypometabolism in the cerebellum and brain- 
stem of patients with hereditary and sporadic OPCA 
E241. The degree of hypometabolism was directly re- 
lated to the severity of the ataxia and to the degree of 
atrophy of these structures in anatomical imaging stud- 
ies C24-261. The present study was undertaken to ex- 
amine local cerebral metabolic rates for glucose 
(1CMRglc) in the central nervous system of patients 
with MSA in comparison with patients with OPCA 
who presented with no clinical evidence of involve- 
ment of autonomic or extrapyramidal systems, and 
with normal control subjects similarly distributed by 
age and sex. We separated the OPCA patients into two 
groups, those with sporadic disease (sOPCA) and those 
with disease inherited in an autosomal dominant pat- 
tern (dOPCA). This separation was made because the 
dOPCA group should constitute a group of pure 
OPCA patients, that is, patients without involvement 
of multiple systems, since people with dOPCA gener- 
ally do not exhibit extrapyramidal or autonomic symp- 
toms. The sOPCA group may include patients with 
clinical symptoms only of OPCA but with pathological 
involvement in multiple systems and with a metabolic 
pattern similar to that seen in MSA, but the dOPCA 
group should be free of such patients. 
The hypothesis underlying this project was that the 
metabolic profile should be different in the three 
groups (MSA, sOPCA, and dOPCA). Based upon the 
sites of degeneration in neuropathological studies, we 
anticipated finding hypometabolism in the basal gan- 
glia, cerebellum, and brainstem in MSA, but only in 
the cerebellum and brainstem in dOPCA. Many pa- 
tients with sOPCA progress to MSA, and thus we an- 
ticipated finding some degree of hypometabolism in 
the basal ganglia, reflecting subclinical disease, in addi- 
tion to involvement of the cerebellum. A preliminary 
communication concerning this study has been pub- 
lished [27] .  
Materials and Methods 
Patient Groups and Normal Subjects 
The studies were approved by the Institutional Review 
Board, and informed consent was obtained from each patient 
and normal control subject. The patients were segregated 
into three groups based upon the history and physical find- 
ings, i.e., multiple system atrophy (MSA), sporadic olivopon- 
tocerebellar atrophy (sOPCA), and dominant olivopontocer- 
ebellar atrophy (dOPCA) (Table 1). We studied 126 subjects 
( 5 1  normal controls and 75 patients), age 5 1  -+ 16 years 
(mean 2 SD), including 59 men (19 normal controls and 40 
patients), age 52 -+ 15 years, and 67 women (32 normal 
controls and 35 patients), age 50 * 16 years. Significant 
differences in age were found among the four diagnosis 
groups ( p  < 0.01) with a one-way analysis of variance (AN- 
OVA). Three patients, two with sOPCA and one with 
dOPCA, were included in our previous studies [24-261, but 
all of these patients were rescanned for the present study. 
One of the patients with sOPCA in the previous communica- 
tions developed extrapyramidal and autonomic symptoms 
and signs subsequent to the initial study and is now in the 
group of MSA patients. 
In analyzing the duration of symptoms, we found that 
skewness in the distribution precluded reporting means and 
standard deviations. Accordingly, we report the range and 
median duration in each group. For MSA the range of dura- 
tion was from 2 to 27 years with a median of 5 years. For 
sOPCA, the range was from 2 to 24 years with a median of 
4 years, and for dOPCA the range was from 2 to 50 years 
Table I .  Numbers, Ages (Mean k SD), and Sex Distributions of the Subjects Studied 
Normal 
Controls dOPCA sOPCA MSA 
n Age (yr) n Age (yr) n Age (yr) n Age (yr) 
Men 19 44 -+ 17 1 1  50 -+ 14 17 56 t 12 12 63 ? 8 
Women 32 44 -+ 18 8 49 -+ 13 15 5 1  +- 1 1  12 65 ? 9 
Total 5 1  44 -+ 17 19 49 -+ 14 32 54 ? 12 24 64 * 8 
dOPCA = dominantly inherited olivopontocerebellar atrophy; sOPCA = sporadic olivopontocerebellar atrophy; MSA = multiple system 
atrophy. 
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Table 2. Clinical Features in  24 Patients with Multiple System Atrophy 
Patient No. 
1 2 3 4 5 6 7 8 9 10 11 12 
Sex F M F F M F F F M F M M 
Age (yr) 59 61 65 82 68 61 58 65 49 16 58 62 
Duration of 
symptoms 
(yr) 4 7 4 3 11 9 2 6 2 5 4 4 
Rigldlty + +  + + +  + + +  + +  + +  - + +  + + +  + +  + + +  + +  + i  





metria + + + + + +  + + - - + +  + +  + 
Gait ataxia + + +  + + +  + + +  + +  - + + +  + + +  + + +  
Limb ataxia + + + +  + +  + + + +  + +  + 
Ataxic speech + + + + +  + +  + +  + + + + + + +  + +  
Spastic speech - + + + + + + + +  + + + + 
tar signs + +  + +  + +  + +  + +  + +  - 
tension + +  + +  + +  + + +  + + +  + +  + +  + +  - - - 
tinence + +  + + +  - + + +  + + +  + +  + +  + + + - 
Cerebral at- 
Cerebellar 
pyramidal) - - - - - - - + + + - - 
speech + +  + +  + +  + + +  + +  + +  + + +  
levodopa NT NT NT NT - + +  - - - 
4- - - 
- - - 
+ + - 





- - - - - 
- 
- 
w h y  + +  + + + 
atrophy + + + +  + +  + +  + +  + +  + 
+ + + - + - - - 
- - - - + +  
( - I = absent, 1 + )  = mild; j + + = moderate: ( + + + )  = marked: NT = nor rested. MRI = magnetic resonance maging 
with a median of 10 years. Studies were performed on nor- 
mal control subjects who had no history of neurological dis- 
order and had no abnormalities on general physical and neu- 
rological examinations (see Table 1). At the time of the PET 
study, none of the patients or normal control subjects were 
taking medications that are known to influence cerebral me- 
tabolism. Four of the 24 patients with MSA were taking 
medications for parkinsonism (carbidopa/levodopa: 25 : 100 
four times daily, 25 : 100 three times daily, 10: 100 four times 
daily along with selegeline 5 mg twice daily, and 10: 100 
three times daily). 
We studied 2 3  patients with probable MSA and 1 patient 
(patient 16) with possible MSA [41. The diagnosis of proba- 
ble MSA was based upon demonstration of clinical signs of 
at least two of the following: (1) extrapyramidal disorder, ( 2 )  
autonomic failure, and ( 3 )  cerebellar dysfunction. For the 
demonstration of extrapyramidal disorder, we required at 
least two of the following signs: akinesia, rigidity, tremor, 
and hypokinetic speech. In most cases we also assessed the 
degree of responsiveness to levodopa with clinical neurologi- 
cal evaluations before and after treatment with carbidopa/ 
levodopa at a dose of 25 : 250, gradually increased from one 
to four tablets daily. Patients were judged to be unresponsive 
or mildly, moderately, or markedly responsive. Seventeen 
patients were tested; 14 were unresponsive, 1 was mildly 
responsive, and 2 were moderately responsive (Table 2). The 
remaining 7 patients could not be tested. 
The demonstration of changes in the putamen in magnetic 
resonance imaging (MRI) scans [28, 291 provided helpful 
information for the diagnosis of MSA but was not required 
since these changes are not specific to MSA 1301. For the 
demonstration of cerebellar dysfunction, we required at least 
two signs, including limb and/or gait ataxia along with ocular 
dysmetria or ataxic speech. For the demonstration of auto- 
nomic failure, we required postural hypotension or urinary 
incontinence without obstruction. The criteria for postural 
hypotension were similar to those of McLeod and Tuck (3 11, 
including an orthostatic drop of 30 mm or more in systolic 
blood pressure and 20 mm or more in diastolic blood pres- 
sure with an increase in heart rate of no more than 10 beats 
per minute. Blood pressure and pulse were measured supine 
and again 2 minutes after the patient had assumed the stand- 
ing position. In patients who could not tolerate standing for 
2 minutes, these changes were accepted after the patient 
stood as long as tolerated. Blood pressure measurements 
were made when the patients had been withdrawn from treat- 
ment with any medication that might induce postural hypo- 
tension. Most of the patients with postural hypotension had 
an associated history of sexual impotence (in the males), an- 
hydrosis, or incontinence without outflow obstruction. Some 
of the patients without postural hypotension had inconti- 
nence without outflow obstruction, and all of these patients 
who were males had sexual impotence. In Table 2, the degree 
of postural hypotension and urinary incontinence refers to 
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Table 2. Continued. 
Patient No. 
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the severity of the symptoms from the patients’ perspective. 
Utilizing the criteria defined above, 13 of the patients had 
extrapyramidal, cerebellar, and autonomic dysfunction, 6 had 
extrapyramidal and autonomic, 3 had extrapyramidal and cer- 
ebellar, 1 had cerebellar and autonomic, and 1 had extrapy- 
ramidal alone (“possible MSA”) (see Table 2). 
The diagnosis of OPCA was based upon a history of pro- 
gressive deterioration in cerebellar function manifested by 
ataxia of gait and speech, usually accompanied by ataxia of 
ocular and limb movements, in the absence of a disorder of 
sensory function sufficient to cause ataxia, medications (e.g., 
phenytoin), toxins (e.g., alcohol), evidence of a neoplasm in 
the cerebellum or elsewhere, or evidence of multiple sclero- 
sis or other diseases that can cause progressive cerebellar 
ataxia. The diagnosis was assisted by the demonstration of 
cerebellar and brainstem atrophy in computed tomographic 
(CT) or  MRI scans, but this was not required since OPCA 
can occur in the absence of atrophy in anatomic imaging 
studies [24}. 
Each patient was evaluated with a complete history, physi- 
cal examination, neurological examination, laboratory tests to 
exclude other diseases, and MRI imaging to exclude demyeli- 
native disease and other structural abnormalities. Speech was 
evaluated as described previously 126, 321. Laboratory tests 
included a complete blood count, serum profiles of hepatic 
and renal function, brainstem auditory, visual, and somato- 
sensory evoked potentials, serum levels of vitamins E and 
B,, and folic acid, and studies of thyroid function. [n patients 
with symptoms for less than 3 years, a search was made for 
an occult malignancy, including breast and pelvic examina- 
tions in women, prostate examination in men, acid phospha- 
tase and prostate specific antigen levels, stool guaiac tests for 
occult blood and chest x-rays. In addition, anti-Purkinje cell 
antibodies were sought in blood samples for patients with 
ataxia of less than 3 years’ duration. All patients were evalu- 
ated with MRI to determine the extent of volume loss of the 
structures under study. The diagnosis of sOPCA was made 
if there was no family history of a similar illness after a de- 
tailed history had been taken with construction of a family 
tree. The diagnosis of dOPCA was based upon a clear family 
history of a similar disorder in a parent. Patients with a family 
history suggesting autosomal recessive inheritance were ex- 
cluded from this study. 
The neurological examinations were conducted by a neu- 
rologist (S.G.) blinded to the PET data. Speech was evaluated 
by a speech-language pathologist (K.J.K.) also blinded to the 
results of the PET studies. The severity of the clinical neuro- 
logical features in the patients with MSA was graded on the 
scales shown in Table 2. 
Positron Emission Tomography Studies 
These studies were performed with the normal control sub- 
jects and the patients lying supine and awake in a quiet room 
with eyes open from 5 minutes before injection until comple- 
tion of the scan. To ensure that similar levels and angles of 
scanning were obtained, all subjects were aligned parallel to 
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the canthomeatal (CM) line with laser beams. Scans were 
performed 30 to 90 minutes after intravenous injection of 
10 mCi of FDG, which was synthesized by an adaptation of 
the method of Hamacher and colleagues 1331. 
PET images were acquired with a SiemensiCTI 93 1/08-12 
scanner, which has an intrinsic in-plane resolution of 5.5-mm 
full-width-at-half-maximum (FWHM) and a z-axis resolution 
of 7.0-mm FWHM. Fifteen planes with 6.75-mm center-to- 
center separation were imaged simultaneously. Two sets of 
interleaved planes were acquired, yielding 30 planes, each 
separated by 3.375 mm. Attenuation correction was calcu- 
lated by fitting ellipses to the scalp contour. 
Blood samples were collected from the radial artery for 
estimation of the arterial radioactivity input to brain. Local 
cerebral metabolic rates for glucose (1CMRglc) were calcu- 
lated with a three-compartment model and a single scan ap- 
proximation [34}. Volumes-of-interest (VOls) were studied 
in the brainstem, cerebellar vermis, cerebellar hemispheres, 
thalamus, basal ganglia (caudate nucleus and putamen), and 
cerebral cortex. Levels comprising each VOI were contigu- 
ous. PET images were viewed in the transverse and sagittal 
planes. Data were collected from transverse sections with a 
2.6-cm2 polygon over each cerebellar hemisphere from 4 of 
the 30 levels, a 1.3-cmZ parallelogram over each thalamus 
from 2 of the 30 levels, a 0.9-cm2 square over each caudate 
nucleus from 2 of the 30 levels, and a 1.9-cm2 parallelogram 
over each putamen from 2 of the 30 levels. Data were col- 
lected in the midsagittal plane from the pons with a 1.3 x 
1.5 x 1. I-cm right parallelepiped and from the superior and 
inferior parts of the cerebellar vermis with a 1.3 X 1.9 X 
1.1-cm right parallelepiped. Each VOI was automatically cen- 
tered over a local peak in 1CMRglc. VOIs from the cerebellar 
vermis were posterior to the fourth ventricle. The brainstem 
VOI chiefly reflects the pons, but the mesencephalon could 
be partially represented. 
Data from the cerebral cortex were obtained in transverse 
images by measuring ICMRglc in the cortical ribbon from 8 
or 10 consecutive planes of 30, beginning with the plane 
containing the most superior portion of the cingulate gyrus 
and continuing inferiorly to the plane containing the lowest 
portion of the thalamus. This was accomplished with an algo- 
rithm that detects the outer edge of the cortical rim from an 
image that has been passed through a contrast-enhancing fil- 
ter. The algorithm then identifies on the original image a 
cortical band that extends inward from this edge until either 
the metabolic rate drops below the value on the outer edge 
of the rim or the band reaches a width of 15 mm. An area- 
weighted mean metabolic rate was computed for the mean 
cortical value. Normalized values were obtained by dividing 
individual VOI values by the mean value from the cerebral 
cortex over all slices. Data were normalized to determine 
whether changes in absolute values reflect the effects of the 
diseases upon specific structures or upon the brain as a whole. 
The cerebral cortex was selected for normalizing the data 
because it is a large structure not known previously to be 
involved in these disorders. 
Data Analysis 
A data analyst (M.L.) analyzed VOIs in the PET studies and 
these data were shared among the investigators only after 
completion of measurements from all studies. Absolute and 
normalized regional glucose cerebral metabolic rates were 
analyzed using multivariate repeated measures analysis of co- 
variance and univariate analysis of covariance (ANCOVA). 
Absolute metabolic rates were analyzed from the following 
seven brain regions: brainstem, cerebellar vermis, cerebellar 
hemispheres, caudate nuclei, putamen, thalamus, and cere- 
bral cortex. Normalized metabolic rates were analyzed for 
the first six of these regions. 
In the multivariate analysis, the dependent variable was 
regional brain metabolic activity (either absolute or normal- 
ized). Measurements on seven (for absolute data) or six (for 
normalized data) brain regions constituted the repeated mea- 
surements on each patient. The primary independent variable 
in the analysis was the categorical variable diagnosis group 
(MSA, sOPCA, dOPCA, or normal control). In addition, the 
factor sex and the continuous covariate age were included in 
the model. All possible interactions between diagnosis group, 
sex, and age were considered. Age was standardized by sub- 
tracting the mean age across all subjects. 
The data were analyzed in several stages. In the first stage, 
not presented here, plots of the data were used to assess 
gross trends and relationships between variables. Second, a 
repeated measures ANOVA model was fitted to the data 
incorporating region as the repeated (within-subject) mea- 
sures variable, diagnosis group, sex, and age, and all of the 
interactions among these variables to determine whether dif- 
ferences existed between brain regions. Dependent upon the 
outcome of this stage, a univariate ANOVA or ANCOVA 
model was developed to examine each region separately. The 
factors incorporated into the univariate ANOVA model 
were those identified in the second stage as having an overall 
effect on glucose metabolic rate across regions or having a 
differential effect on glucose metabolic rates between re- 
gions. In the last stage, comparisons of individual diagnosis 
group means were made, where appropriate. 
For all pairwise differences, a Tukey-Kramer multiple 
comparison adjustment 1351 was used. Hence, the reported 
p values incorporate this adjustment. When the final model 
included age, diagnosis group means were appropriately ad- 
justed for age. Data analysis was performed with the SAS 
statistical package (SAS Institute Inc., Cary, NC). 
Results 
Analysis of Ahofute h e f s  of ICMRgfc 
Repeated measures ANCOVA revealed highly sig- 
nificant differences between brain regions ( p  < 
0.0001) and strong evidence for differences in the ef- 
fects of diagnosis group between regions ( p  < 0.0001). 
Evidence was found also for differences in region by 
age ( p  < 0.005). No evidence was adduced for differ- 
ences in region by sex, nor for differences between 
regions in interaction effects between age, sex, or diag- 
nosis group. Examination of the overall effects of diag- 
nosis, age, and sex (looking across all regions simulta- 
neously) indicated large differences between diagnosis 
groups ( p  < 0.0001) but no other significant effects. 
The significant effects found between regions, and 
differences in the effects of diagnosis groups, indicate 
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that differences in metabolic rates between diagnosis 
groups must be examined for each region individually. 
The evidence for a difference in age effect by region 
requires that this variable be incorporated in the uni- 
variate analysis as a covariate. 
Separate univariate ANCOVA analyses for each re- 
gion (including the factors diagnosis and age) revealed 
that age effects were significant in the caudate nucleus 
( p  = 0.0003), putamen ( p  = 0.021), and cerebral cor- 
tex ( p  = 0.0008). In the thalamus there was some 
indication of a trend with age ( p  = 0.06). No evidence 
was found in any of the remaining regions for an age 
effect ( p  > 0.10 in each). To provide a common basis 
for comparison, however, subsequent analysis of abso- 
lute metabolic rates by diagnosis group incorporated 
an adjustment for age. 
Very strong evidence was found for overall differ- 
ences in diagnosis groups in the brainstem, cerebellar 
vermis, cerebellar hemispheres, and putamen ( p  < 
0.0001 in each). Strong evidence for overall differ- 
ences in diagnosis groups was also found in the thala- 
mus ( p  = 0.0016) and cerebral cortex ( p  = 0.004). 
Evidence for a difference in caudate nucleus was also 
found ( p  = 0.041). To investigate these differences 
further, pairwise comparisons among mean ICMRglc 
values were examined. 
After controlling for multiple comparisons, we 
found that in MSA, absolute lCMRglc was markedly 
and significantly decreased relative to normals in the 
brainstem, cerebellar vermis, cerebellar hemispheres, 
and putamen ( p  < 0.0001 in each) and also in the 
thalamus and cerebral cortex ( p  < 0.05 in each) (Table 
3 ,  Fig). In sOPCA, lCMRglc was decreased in the 
brainstem, cerebellar vermis and cerebellar hemi- 
spheres ( p  < 0.0001 in each), and putamen ( p  < O.OI), 
but somewhat less in the cerebral cortex and thalamus 
( p  < 0.05). In dOPCA, lCMRglc was greatly decreased 
in the brainstem, cerebellar vermis, and cerebellar 
hemispheres ( p  < 0.0001 in each), but no other re- 
gions showed significant decreases. Statistically signifi- 
cant differences between MSA and dOPCA were 
found in the putamen ( p  = 0.02) only. 
Analysis of lCMRglc Normalized 
to the Cerebral Cortex 
Repeated measures ANCOVA revealed highly sig- 
nificant differences between brain regions ( p  < 
0.0001) and strong evidence for differences in the ef- 
fects of diagnosis group between regions ( p  < 0.0001). 
Evidence was found also for differences in region by 
age ( p  < 0.02). No evidence was adduced for differ- 
ences in the effects of region by sex, nor for differences 
between regions in interaction effects between age, 
sex, or diagnosis group. Examination of the overall ef- 
fects of diagnosis, age, and sex (looking across all re- 
gions simultaneously) indicated strong differences be- 
Table 3. Absolute Local Cerebral Metabolic Rates for Glucase 
Normal 
Controls dOPCA sOPCA MSA 
Structure (n = 51) (n = 17) (n = 32) (n = 24) 
Brainstem 5.98 4.74" 4.50" 4.08" 
Cerebellar 6.25 4.77" 4.42" 4.37" 
Cerebellar 6.71 5.10" 4.76" 4.24" 
Thalamus 8.67 8.27ns 7.81d 7.39' 
Caudate nuclei 8.00 7.56"s 7.36"s 7 .WnS 
Putamen 8.69 8.3OnS 7.71' 7.02" 
Cerebral cortex 6.88 6.64"s 6.26d 6.00' 
Values are mean absolute glucose metabolic rates adjusted for age 
effects. Significant differences in comparison with normal controls via 
pairwise comparisons with a Tukey-Gamer adjustment for multiple 
comparisons: ' p  < 0.0001, ' p  < 0.01, ' p  < 0.05, "' = not significant. 
dOPCA = dominantly inherited olivopontocerebellar atrophy; 




tween diagnosis groups ( p  < 0.0001) and evidence for 
age effects ( p  < 0.001) but no other significant effects. 
The significant effects found between regions and 
differences in the effects of diagnosis groups indicated 
that differences in metabolic rates between diagnosis 
groups must be examined for each region individually 
via a one-way ANOVA on diagnosis group. The evi- 
dence of differences in age effects by region and an 
overall age effect require that age be incorporated in 
the univariate analysis with an ANCOVA by region. 
Separate univariate analysis for each region (includ- 
ing the factor diagnosis and the covariate age) demon- 
strated that age effects were significant in the brainstem 
( p  = 0.012), cerebellar vermis ( p  = 0.005), cerebellar 
hemispheres ( p  = 0.007'), and thalamus ( p  = 0.017). 
In the caudate nucleus there was some indication of a 
trend with age ( p  = 0.06), but no evidence for an age 
effect was found in the putamen ( p  > 0.10). To  pro- 
vide a common basis for comparison, subsequent anal- 
yses of normalized metabolic rates by diagnosis group 
included an adjustment for age in all regions. 
Very strong evidence was found for overall differ- 
ences in diagnosis groups in brainstem, cerebellar ver- 
mis, and cerebellar hemispheres ( p  < 0.0001 in each). 
Strong evidence for overall differences in diagnosis 
groups was also found in the putamen ( p  = 0.01). 
N o  evidence was found for differences in the caudate 
nucleus or thalamus ( p  > 0.10). To investigate these 
differences further, pairwise comparisons among mean 
lCMRglc values were examined. 
After controlling for multiple comparisons, we 
found that in MSA, normalized lCMRglc was markedly 
and significantly decreased relative to normals in the 
brainstem, cerebellar vermis, and cerebellar hemi- 
spheres ( p  < 0.0001 in each) and also in the putamen 
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Positron emission tomography scans showing local cerebral meta- 
bolic rate for glucose ClCMRglc) as detected with ['8F}f2tloro- 
deoxyglucose in a mule normal control subject age 52 (left upper 
and lower images), a male patient age 61 with multiple system 
atrophy (MSA, upper and lower images second from the 
left), a male patient age 46 with sporadic olivopontocerebellar at- 
rophy (sOPCA, upper and lower images third from the Ieft), 
and a male patient age 37 with dominant4 inherited olivopon- 
tocerebellar atrophy (dOPCA, right upper and lower images). 
All scans in the upper row shouJ horizontal sections at the level 
of the cerebral cortex, basal ganglia, and thalamus, and all 
scans in the lower row show horizontal sections at the level o f  
the cerebellum and the base ofthe temporal and frontal lobes. 
The color bar indicates the rate of cerebral glucose utilization 
for all scans illustrated expressed as milligrams per 100 grams 
per minute extending from 0.0 to 10.5. Note the decreased 
lCMRglc in the brainstem and cerebellum o f  all 3 patients in 
comparison with the normal control subject. There is decreased 
lCMRglc also in the cerebral cortex and basal ganglia of the pa- 
tients with MSA and sOPCA but n o t  dOPCA. 
( p  < 0.01) (Table 4). In both sOPCA and dOPCA, 
lCMRglc was decreased in the brainstem, cerebellar 
vermis, and cerebellar hemispheres ( p  < 0.0001 in 
each). No statistically significant differences between 
MSA and dOPCA were found. 
Neuropathological Findings 
Four of the 14 patients with MSA in the present study 
have died and come to neuropathological examination. 
The diagnosis of MSA was confirmed in 3 of these 
patients by the marked degenerative changes, including 
loss of neurons and gliosis, in the inferior olives, pons, 
cerebellum, substantia nigra, and posterior lateral as- 
pects of the putamen. There was no involvement of 
the anterior thalamus, caudate nucleus, hypothalamus, 
or the frontal, parietal, temporal, and occipital regions 
of the cerebral cortex. The fourth patient survived car- 
diac arrest and lingered in a vegetative state for 4 
weeks before succumbing. The preexistent neuropath- 
ological changes in the forebrain could not be estab- 
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Table 4. Local Cerebral Metabolic Rates for Glucose Normalized 
to the Cerebral Cortex 
Normal 
Conrrols dOPCA sOPCA MSA 
Structure (n = 51) (n = 19) (n = 32) (n = 24) 
Brainstem 0.86 0.71" 0.73a 0.68" 
Cerebellar 0.91 0.72" 0.71" 0.73" 
Cerebellar 0.98 0.76" 0.77" 0.71" 
Thalamus 1.26 1.24"s 1.26ns 1.24"= 
Caudate nuclei 1.16 1.13"s 1.1SnS 1.1SnS 
Putamen 1.26 1.25"s 1.24"s 1.17' 
Values are mean cerebral glucose metabolic rates normalized to cere- 
bral cortex and adjusted for age effects. Significant differences in 
comparison to normal controls via pairwise comparisons with Tu- 
key-Gamer adjustment for multiple comparisons: 'p < 0.0001, 
'p < 0.01, "' = not significant. 
dOPCA = dominantly inherited olivopontocerebellar atrophy; 




lished because of extensive hypoxic-ischemic tissue 
damage, but degenerative and atrophic changes were 
found in the inferior olives, pons, and cerebellum. 
Discussion 
We found in all three groups of patients, MSA, sOPCA 
and dOPCA, a marked and significant decrease of ab- 
solute lCMRglc in the brainstem and cerebellar vermis 
and hemispheres. MSA patients showed additionally a 
marked and significant decrease in the putamen, and a 
mild but significant decrease in the thalamus and cere- 
bral cortex, but no significant change in the caudate 
nucleus. Patients with sOPCA showed, in addition, a 
mild but significant decrease in the putamen, thalamus, 
and cerebral cortex and no change in the caudate nu- 
cleus. Patients with dOPCA showed no significant dif- 
ferences in other structures, including the thalamus, 
putamen, caudate nucleus, and cerebral cortex. Thus, 
distinctive regional patterns of decreased ICMRglc are 
found in all three disorders, with more similarity be- 
tween sOPCA and MSA than between dOPCA and 
either MSA or sOPCA. 
Comparison of 1CMRglc in the putamen among the 
three groups of diseases disclosed (1) a large and sig- 
nificant reduction in MSA, (2) a significant reduction 
in sOPCA but not as large as that seen in MSA, and (3) 
no significant change in dOPCA. Since patients with 
sOPCA can progress to develop MSA, it is possible 
that the moderate reduction of lCMRglc in the puta- 
men in these patients may represent the development 
of neuropathological changes typical of MSA, although 
clinical signs diagnostic of MSA were not detectable at 
the time of study. 
When the ICMRglc data were normalized to the ce- 
rebral cortex, all three groups of patients showed a 
marked and significant decrease in the brainstem and 
cerebellum. In MSA patients a mild but significant de- 
crease was found also in the putamen. In sOPCA and 
dOPCA patients, no other regions showed significant 
changes. These findings reflect the severe involvement 
of the brainstem and cerebellum in all three disorders 
and the greater involvement of the putamen in MSA 
than in the other two entities. None of the other re- 
gions that were significantly affected in the analysis of 
absolute data in sOPCA and MSA groups showed sig- 
nificant changes in the normalized data because these 
regions were all mildly affected to about the same 
degree. 
The finding of markedly reduced 1CMRglc in the 
putamen as well as the brainstem and cerebellum in 
MSA patients is in keeping with the neuropathological 
changes in this disease [4,  8, 9,  12, 14, 153 and, to 
some extent, with previous PET studies 136-381. De- 
generative changes in MSA are prominent in the puta- 
men, substantia nigra, and locus ceruleus and also com- 
monly affect the inferior olives, pons, and cerebellum 
12, 4,  81. Thus, hypometabolism in the putamen, as 
well as the brainstem and cerebellum, reflects the loss 
of neurons and synaptic connections in these sites. 
Many other sites can be affected neuropathologically 
in MSA, including the cerebral cortex, caudate nucleus, 
and globus pallidus (especially the external portion), 
but the thalamus is only rarely involved. Thalamic 
involvement when present is probably due to deaffer- 
entation secondary to degeneration of striatothalamic 
projections, which is evident in the ansa lenticularis 
and fasciculus lenticularis. The finding of normal glu- 
cose metabolic rates in the caudate nucleus of MSA 
patients in the present study indicates that this site was 
not appreciably affected in our cases, but the hypome- 
tabolism found in the cerebral cortex suggests that this 
site is either directly affected or shows the effects of 
deafferentation. The finding of decreased glucose met- 
abolic rates in the cerebral cortex suggests that PET 
studies with FDG can demonstrate disturbances not 
detected with conventional neuropathological tech- 
niques. 
The finding of significantly reduced ICMRglc in the 
brainstem and cerebellum in both sOPCA and dOPCA 
is in keeping with the primary neuropathological pro- 
cess in OPCA, which involves neuronal loss and gliosis 
within the inferior olives, pons, and cerebellum { 2 ,  
19-23]. The decreased metabolic rates in these struc- 
tures reflect the reduced numbers of neurons and syn- 
aptic connections, though partial volume effects from 
tissue atrophy may be important. Although many other 
central nervous system structures can show neuropath- 
ological findings in OPCA [2, 19-23}, the finding of 
reduced ICMRglc so widely throughout the brain in 
patients with sOPCA in this study, including the basal 
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ganglia, thalamus, and cerebral cortex, is unexpected involvement in extrapyramidal and cerebellar disorders. Clin 
but may suggest that (1) this disorder affects many 
more structures in the central nervous system than 
conventional neuropathological studies have disclosed, 
(2) the sites showing primary degenerative changes in- 
fluence other structures through transneuronal effects, 
or (3) these patients are beginning to develop MSA. 
Several investigators have examined ICMRglc in 
small numbers of MSA patients. De Volder and col- 
leagues 1361 studied 7 patients with probable SND 
compared with 16 neurologically normal control sub- 
jects by using FDG and PET. All 7 patients had extra- 
pyramidal symptoms poorly responsive or unrespon- 
sive to levodopa, and 2 of the 7 had signs of cerebellar 
disorder accompanied by autonomic disturbances. Glu- 
cose utilization was significantly decreased in the pa- 
tients with SND in the putamen, caudate nucleus, and 
frontal regions of the cerebral cortex but not in the 
thalamus or cerebellum. In the 2 patients with cerebel- 
lar symptoms, however, hypometabolism was found 
within the cerebellum. Moreover, a third patient 
scanned twice showed clinical signs of cerebellar disor- 
der at the time of the second scan, and only this scan 
demonstrated cerebellar hypometabolism. Our pa- 
tients differed from those of De Volder and colleagues 
[36] in that we had more who had involvement of the 
cerebellum. Fulham and associates 137) studied 8 MSA 
patients in comparison with 18 normal control subjects 
by using FDG and PET and found hypometabolism in 
the cerebellar vermis, cerebellar hemispheres, stria- 
turn, and frontal cortex. Four of their 8 patients had 
prominent signs of cerebellar disorder. Their findings 
are similar to those in our MSA patients. Eidelberg 
and co-workers 1381 reported finding hypometabolism 
in the caudate nucleus and putamen of 10 patients 
with striatonigral degeneration in comparison with 10 
normal control subjects and 20 patients with Parkin- 
son’s disease by using FDG and PET. They found no 
metabolic changes in other cortical or subcortical re- 
gions. 
This study was supported in part by grants NS 15655 and AGO867 1 
from the National Institutes of Health. 
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